Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Drugs

Darbepoetin alfa Product Approval Information - Licensing Action 9/17/01

Proper name: Darbepoetin alfa
Tradename: Aranesp
Manufacturer: Amgen, Inc, Thousand Oaks, CA, License #1080
Indication for Use: Treatment of anemia associated with chronic renal failure, including patients on dialysis and patients not on dialysis
Approval Date: 9/17/2001
Type of submission: Biologics license application

 


Approval Letter (PDF)

Label (PDF)

Patient Package Insert (PDF)

CMC Review (PDF)

Medical Officer (PDF)

Clinical Pharm (PDF)

Statistical (PDF)

Immunogenicity (PDF)

Toxicology (PDF)

Page Last Updated: 10/04/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English